BACKGROUND: QuantiFERON enzyme-linked immunosorbent assay (ELISA; Qiagen) with Borrelia burgdorferi peptide antigens was previously shown to reliably detect interferon-γ (IFN-γ) in blood samples from adult patients with early Lyme disease and the response disappeared rapidly after treatment. We evaluated the response before and after appropriate antibiotic therapy in adolescent and adult subjects with more diverse stages of the illness. METHODS: Blood was obtained from patients with clinician-identified Lyme disease with constitutional complaints, erythema migrans, nerve palsy, cardiac abnormality, or arthritis before (n = 68) and 6 weeks (n = 46) and 6 months (n = 45) after therapy. The sera were tested for Lyme disease by standard 2-tiered testing (STTT) and anti-C6 antibodies by ELISA and the levels of IFN-γ in the blood samples were detected by QuantiFERON ELISA. RESULTS: A positive STTT result supported the clinical diagnosis of 37 (54%) subjects and anti-C6 antibodies were detected in 45 (66%) subjects, including 36 (97%) STTT-positive subjects, and the responses often persisted or expanded after antibiotic therapy. IFN-γ was detected in 49 (72%) subjects prior to treatment and the response most often significantly decreased 6 weeks (P = .007) or 6 months (P = .001) after treatment. CONCLUSIONS: The QuantiFERON ELISA reliably detected IFN-γ in blood samples from adult and adolescent patients with varying stages of Lyme disease and the response disappeared rapidly after treatment. Additional studies to more critically evaluate clinical utility as a laboratory test for diagnosis and confirmation of effective therapy are warranted.
BACKGROUND: QuantiFERON enzyme-linked immunosorbent assay (ELISA; Qiagen) with Borrelia burgdorferi peptide antigens was previously shown to reliably detect interferon-γ (IFN-γ) in blood samples from adult patients with early Lyme disease and the response disappeared rapidly after treatment. We evaluated the response before and after appropriate antibiotic therapy in adolescent and adult subjects with more diverse stages of the illness. METHODS: Blood was obtained from patients with clinician-identified Lyme disease with constitutional complaints, erythema migrans, nerve palsy, cardiac abnormality, or arthritis before (n = 68) and 6 weeks (n = 46) and 6 months (n = 45) after therapy. The sera were tested for Lyme disease by standard 2-tiered testing (STTT) and anti-C6 antibodies by ELISA and the levels of IFN-γ in the blood samples were detected by QuantiFERON ELISA. RESULTS: A positive STTT result supported the clinical diagnosis of 37 (54%) subjects and anti-C6 antibodies were detected in 45 (66%) subjects, including 36 (97%) STTT-positive subjects, and the responses often persisted or expanded after antibiotic therapy. IFN-γ was detected in 49 (72%) subjects prior to treatment and the response most often significantly decreased 6 weeks (P = .007) or 6 months (P = .001) after treatment. CONCLUSIONS: The QuantiFERON ELISA reliably detected IFN-γ in blood samples from adult and adolescent patients with varying stages of Lyme disease and the response disappeared rapidly after treatment. Additional studies to more critically evaluate clinical utility as a laboratory test for diagnosis and confirmation of effective therapy are warranted.
Authors: Peggy Coulter; Clara Lema; Diane Flayhart; Amy S Linhardt; John N Aucott; Paul G Auwaerter; J Stephen Dumler Journal: J Clin Microbiol Date: 2005-10 Impact factor: 5.948
Authors: John A Branda; Klemen Strle; Lise E Nigrovic; Paul M Lantos; Timothy J Lepore; Nitin S Damle; Mary Jane Ferraro; Allen C Steere Journal: Clin Infect Dis Date: 2017-04-15 Impact factor: 9.079
Authors: Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman Journal: Clin Infect Dis Date: 2006-10-02 Impact factor: 9.079
Authors: Mona Widhe; Sara Jarefors; Christina Ekerfelt; Magnus Vrethem; Sven Bergstrom; Pia Forsberg; Jan Ernerudh Journal: J Infect Dis Date: 2004-04-26 Impact factor: 5.226
Authors: Marika Nordberg; Pia Forsberg; Dag Nyman; Barbro H Skogman; Clara Nyberg; Jan Ernerudh; Ingvar Eliasson; Christina Ekerfelt Journal: Cells Date: 2012-06-08 Impact factor: 6.600
Authors: T van Gorkom; W Voet; S U C Sankatsing; C D M Nijhuis; E Ter Haak; K Kremer; S F T Thijsen Journal: Clin Exp Immunol Date: 2020-01-07 Impact factor: 4.330
Authors: Rendi Murphree Bacon; Brad J Biggerstaff; Martin E Schriefer; Robert D Gilmore; Mario T Philipp; Allen C Steere; Gary P Wormser; Adriana R Marques; Barbara J B Johnson Journal: J Infect Dis Date: 2003-04-02 Impact factor: 5.226
Authors: Frederik R van de Schoor; Hedwig D Vrijmoeth; Michelle A E Brouwer; Hadewych J M Ter Hofstede; Heidi L M Lemmers; Helga Dijkstra; Collins K Boahen; Marije Oosting; Bart-Jan Kullberg; Joppe W Hovius; Cees C van den Wijngaard; Frank L van de Veerdonk; Mihai G Netea; Leo A B Joosten Journal: Infect Immun Date: 2022-02-07 Impact factor: 3.609